In this umbrella review of 60 meta-analyses encompassing 1,751 randomized clinical trials and approximately 3.6 million participants, glucagon-like peptide-1 receptor agonists were most consistently associated with increased gastrointestinal adverse events, including nausea, vomiting, and diarrhea, while showing potential protective associations with serious infections and respiratory disease. However, most noncardiometabolic outcomes—including neurologic, psychiatric, cancer, and hepatobiliary events—were supported by low-certainty or exploratory evidence, limiting clinical interpretability and precluding changes to current prescribing practices.

Source: JAMA Network Open